FUNROOTS Co., Ltd. (Tokyo, Japan), I Peace, Inc. (California, USA), and Reju Inc. (Tokyo, Japan) entered a strategic partnership to integrate cutting-edge iPS cell technology into the sports industry, aiming to deliver innovative health management solutions, enhance athletic performance, and accelerate injury recovery, leveraging advancements in regenerative medicine. [Read more…]
Pioneering the future of sports with iPS cells
Nikon CeLL Innovation Enters into a Strategic License Agreement with RoosterBio, a US Company, to Enable GCTP/GMP Manufacturing Platform of Human Mesenchymal Stem Cells & Extracellular Vesicle in Japan
TOKYO – Nikon CeLL innovation Co., Ltd. (NCLi), a subsidiary of Nikon Corporation has entered into a strategic licensing agreement with RoosterBio, Inc. (RoosterBio), a leading stem cell technology company in the US.
This agreement provides the Japanese biopharma industry with an end-to-end solution for development and manufacturing of human mesenchymal stem cells (MSC) and extracellular vesicle (EV) therapeutics. Drug developers can leverage RoosterBio’s technology platform to accelerate the development of their advanced therapies with NCLi, and then seamlessly transition to clinical manufacturing within NCLi’s GCTP*1/GMP*2 facility designed specifically for cell therapies. [Read more…]
Curi Bio and Cook MyoSite Announce Strategic Partnership
Curi Bio and Cook MyoSite Announce Strategic Scientific Collaboration to Advance Translational Human Muscle Disease Models
SEATTLE & PITTSBURGH — Curi Bio, the global leader in human 3D engineered tissue platforms, and Cook MyoSite, a pioneer in the development of skeletal muscle-based therapies, today announced a strategic partnership to develop advanced, predictive human engineered tissue models aimed at addressing muscle-related diseases and metabolic disorders, including obesity and diabetes. [Read more…]
RoosterBio Announces Collaboration with Thermo Fisher Scientific to Advance Cell and Exosome Therapy Manufacturing
FREDERICK, MD., (April 29, 2025) —RoosterBio, Inc., a leading supplier of adult human mesenchymal stem/stromal cells (hMSCs), highly engineered media, and bioprocess development services, announced a new collaboration with Thermo Fisher Scientific, the world leader in serving science. This collaboration aims to accelerate the availability of new, potentially life-saving cell and exosome therapies that have the potential to revolutionize the treatment of degenerative disease. [Read more…]
Cellistic Launches Echo™ – NK Platform, a Scalable Solution for Off-the-Shelf Allogeneic Immune Cell Therapies
Belgium, Mont Saint-Guibert, April 10 – Cellistic, a pioneer in induced pluripotent stem cells (iPSC)-based cell therapies, is launching the Echo™-NK platform to enable the scalable manufacturing of allogeneic cell therapies to target multiple diseases. Natural Killer (NK) cells are increasingly leveraged in these therapies for their ability to destroy harmful cancerous cells in their early stages, making them a promising option for the treatment of blood cancers, solid tumors, and autoimmune diseases. Cellistic’s Echo™-NK platform provides drug developers with a commercially viable solution for an Off-the-Shelf NK cell therapy. [Read more…]
- « Previous Page
- 1
- …
- 14
- 15
- 16
- 17
- 18
- …
- 20
- Next Page »